Stock GNFT GENFIT
Add to a list
To use this feature you must be a member
Log inSign up

Financials GENFIT

Equities

GNFT

FR0004163111

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:02 2024-04-26 am EDT 		5-day change 1st Jan Change
3.21 EUR +1.58% Intraday chart for GENFIT +1.58% -9.32%
Apr. 26 European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT
Apr. 24 European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 684.6 154.9 214.6 197 176 159.6 - -
Enterprise Value (EV) 1 591.4 169.6 30.1 131.8 168.4 132 114.7 159.6
P/E ratio -10 x -1.54 x 3.51 x -8.27 x -6.1 x 6.83 x 24.7 x -
Yield - - - - - - - -
Capitalization / Revenue 16.7 x 20 x 2.51 x 7.42 x 4.61 x 1.78 x 3.27 x 1.52 x
EV / Revenue 14.4 x 21.9 x 0.35 x 4.96 x 4.41 x 1.47 x 2.35 x 1.52 x
EV / EBITDA -11.3 x -2.29 x 0.87 x -5.18 x -6.75 x 4.41 x 13.2 x -
EV / FCF -11.9 x -1.74 x 0.3 x - -3.02 x 47.1 x 6.67 x -
FCF Yield -8.41% -57.4% 330% - -33.2% 2.12% 15% -
Price to Book 8.16 x -9.5 x 2.55 x - 2.59 x 2.06 x 1.9 x -
Nbr of stocks (in thousands) 38,785 38,811 49,727 49,655 49,712 49,713 - -
Reference price 2 17.65 3.992 4.316 3.968 3.540 3.210 3.210 3.210
Announcement Date 4/8/20 4/1/21 4/7/22 4/13/23 4/4/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 40.96 7.758 85.58 26.57 38.18 89.63 48.78 105.2
EBITDA 1 -52.43 -74.03 34.56 -25.46 -24.93 29.9 8.7 -
EBIT 1 -57.83 -77.59 31.82 -27.29 -26.58 14.92 -28.56 89.27
Operating Margin -141.19% -1,000.12% 37.18% -102.72% -69.62% 16.64% -58.55% 84.89%
Earnings before Tax (EBT) 1 -65.72 -101.6 69.47 -23.84 -28.51 27.36 -23.13 54.24
Net income 1 -65.14 -101.2 67.26 -23.72 -28.89 15.26 -21.06 38.45
Net margin -159.04% -1,304.73% 78.59% -89.28% -75.69% 17.03% -43.16% 36.56%
EPS 2 -1.760 -2.600 1.230 -0.4800 -0.5800 0.4700 0.1300 -
Free Cash Flow 1 -49.71 -97.27 99.38 - -55.84 2.8 17.2 -
FCF margin -121.36% -1,253.82% 116.12% - -146.28% 3.12% 35.26% -
FCF Conversion (EBITDA) - - 287.57% - - 9.36% 197.7% -
FCF Conversion (Net income) - - 147.75% - - 18.34% - -
Dividend per Share 2 - - - - - - - -
Announcement Date 4/8/20 4/1/21 4/7/22 4/13/23 4/4/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 35.6 5.867 1.891 3.428 82.15 12.19 14.38 15.37 22.8 44.6 50.82
EBITDA - - - - - - - - - - -
EBIT 1 -11.9 -49.16 -28.43 -29.55 61.37 -14.34 -12.94 -19.3 -7.281 15.16 11.2
Operating Margin -33.41% -837.96% -1,503.23% -862.05% 74.7% -117.69% -90.03% -125.53% -31.93% 33.99% 22.03%
Earnings before Tax (EBT) 1 -14.3 -53.17 -48.48 6.163 63.31 -10.36 -13.48 -20.44 -8.074 15.66 11.7
Net income 1 -14.01 -53.01 -48.21 9.058 58.2 -10.4 -13.32 -20.85 -8.04 10.83 15.65
Net margin -39.36% -903.55% -2,549.44% 264.24% 70.85% -85.32% -92.64% -135.64% -35.26% 24.28% 30.79%
EPS -0.1200 - - - - - - -0.4200 - - -
Dividend per Share - - - - - - - - - - -
Announcement Date 4/8/20 9/30/20 4/1/21 9/29/21 4/7/22 9/28/22 4/13/23 9/20/23 4/4/24 - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 14.7 - - - - - -
Net Cash position 1 93.1 - 185 65.3 7.61 27.6 44.9 -
Leverage (Debt/EBITDA) - -0.1981 x - - - - - -
Free Cash Flow 1 -49.7 -97.3 99.4 - -55.8 2.8 17.2 -
ROE (net income / shareholders' equity) -124% -283% - -22.2% -35.6% 36% 8.2% -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 2.160 -0.4200 1.690 - 1.370 1.560 1.690 -
Cash Flow per Share 2 -1.290 -2.480 1.800 - -1.120 -0.2000 -0.7000 1.900
Capex 1 2.03 0.9 0.54 - 0.41 0.1 0.1 0.2
Capex / Sales 4.96% 11.6% 0.63% - 1.08% 0.11% 0.2% 0.19%
Announcement Date 4/8/20 4/1/21 4/7/22 4/13/23 4/4/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for GENFIT

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.21 EUR
Average target price
9.38 EUR
Spread / Average Target
+192.21%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENFIT Stock GENFIT
-9.32% 170M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GNFT Stock
  4. Financials GENFIT